C-MYC/BCL6 DOUBLE-HIT HIGH-GRADE B-CELL LYMPHOMA

Clinical trials for C-MYC/BCL6 DOUBLE-HIT HIGH-GRADE B-CELL LYMPHOMA explained in plain language.

Never miss a new study

Get alerted when new C-MYC/BCL6 DOUBLE-HIT HIGH-GRADE B-CELL LYMPHOMA trials appear

Sign up with your email to follow new studies for C-MYC/BCL6 DOUBLE-HIT HIGH-GRADE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New combo therapy fights back against stubborn blood cancers

Disease control Ongoing

This study is testing if adding the drug acalabrutinib to a personalized cell therapy (liso-cel) is safe and effective for adults with aggressive B-cell lymphomas that have come back or not responded to at least two prior treatments. Participants receive a one-time infusion of th…

Matched conditions: C-MYC/BCL6 DOUBLE-HIT HIGH-GRADE B-CELL LYMPHOMA

Phase: PHASE2 • Sponsor: Patrick C. Johnson, MD • Aim: Disease control

Last updated Mar 27, 2026 12:37 UTC

C-MYC/BCL6 DOUBLE-HIT HIGH-GRADE B-CELL LYMPHOMA

Get alerted when new C-MYC/BCL6 DOUBLE-HIT HIGH-GRADE B-CELL LYMPHOMA trials appear

New combo therapy fights back against stubborn blood cancers